D E Neal
Overview
Explore the profile of D E Neal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
249
Citations
4093
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sutton E, Lane J, Davis M, Walsh E, Neal D, Hamdy F, et al.
Cancer Causes Control
. 2021 Jan;
32(3):261-269.
PMID: 33394204
Purpose: To investigate men's experiences of receiving external-beam radiotherapy (EBRT) with neoadjuvant Androgen Deprivation Therapy (ADT) for localized prostate cancer (LPCa) in the ProtecT trial. Methods: A longitudinal qualitative interview...
2.
Patel K, van der Vos K, Smith C, Mouliere F, Tsui D, Morris J, et al.
Sci Rep
. 2017 Jul;
7(1):5554.
PMID: 28717136
Muscle Invasive Bladder Cancer (MIBC) has a poor prognosis. Whilst patients can achieve a 6% improvement in overall survival with Neo-Adjuvant Chemotherapy (NAC), many do not respond. Body fluid mutant...
3.
Lane J, Oliver S, Appleby P, Lentjes M, Emmett P, Kuh D, et al.
Eur J Clin Nutr
. 2017 Mar;
71(4):567.
PMID: 28294171
No abstract available.
4.
Ross-Adams H, Lamb A, Dunning M, Halim S, Lindberg J, Massie C, et al.
EBioMedicine
. 2017 Mar;
17:238.
PMID: 28292578
No abstract available.
5.
Lane J, Oliver S, Appleby P, Lentjes M, Emmett P, Kuh D, et al.
Eur J Clin Nutr
. 2016 Sep;
71(2):274-283.
PMID: 27677361
Background/objectives: The influence of dietary factors remains controversial for screen-detected prostate cancer and inconclusive for clinically detected disease. We aimed to examine these associations using prospectively collected food diaries. Subjects/methods:...
6.
Donovan J, Hamdy F, Lane J, Mason M, Metcalfe C, Walsh E, et al.
N Engl J Med
. 2016 Sep;
375(15):1425-1437.
PMID: 27626365
Background: Robust data on patient-reported outcome measures comparing treatments for clinically localized prostate cancer are lacking. We investigated the effects of active monitoring, radical prostatectomy, and radical radiotherapy with hormones...
7.
Mason M, MOORE R, Jones G, Lewis G, Donovan J, Neal D, et al.
Clin Oncol (R Coll Radiol)
. 2016 Jul;
28(9):e92-e100.
PMID: 27425582
Aims: The treatment of prostate cancer has evolved markedly over the last 40 years, including radiotherapy, notably with escalated dose and targeting. However, the optimal treatment for localised disease has...
8.
Ross-Adams H, Lamb A, Dunning M, Halim S, Lindberg J, Massie C, et al.
EBioMedicine
. 2015 Oct;
2(9):1133-44.
PMID: 26501111
Background: Understanding the heterogeneous genotypes and phenotypes of prostate cancer is fundamental to improving the way we treat this disease. As yet, there are no validated descriptions of prostate cancer...
9.
Mitchell T, Neal D
Br J Cancer
. 2015 Jul;
113(2):193-8.
PMID: 26125442
Prostate cancers are highly prevalent in the developed world, with inheritable risk contributing appreciably to tumour development. Genomic heterogeneity within individual prostate glands and between patients derives predominantly from structural...
10.
Wong L, Neal D, Finelli A, Davis S, Bonner C, Kapoor J, et al.
Prostate Cancer Prostatic Dis
. 2015 Feb;
18(2):137-43.
PMID: 25667108
Background: In an era of personalized medicine, individualized risk assessment using easily available tools on the internet and the literature are appealing. However, uninformed use by clinicians and the public...